Listed by the USPTO as BORI, IBRAHIM D
Tech Center 1600 • Art Units: 1622 1629
This examiner grants 44% of resolved cases
Ibrahim D. Bori serves in Tech Center 1600 and Art Unit 1622. Bori has 615 resolved cases and an allowance rate of 43.9 percent. This rate suggests a challenging environment for applicants in biotechnology and organic chemistry. Practitioners should be prepared for a rigorous examination process where less than half of the applications reach a grant.
The interview lift is 39.0 percent, which is a very high figure indicating that interviews are a critical strategy for securing an allowance compared to cases without them. This suggests that direct engagement is highly effective in resolving rejections. The median days to allowance is 1258, reflecting a longer and potentially more difficult prosecution process for successful applications.
Nestlé S.A., AMOREPACIFIC Corporation, and Zogenix are major companies in Bori's docket. Firms like K&L Gates LLP and Sterne, Kessler, Goldstein & Fox P.L.L.C. are frequently involved. These data points highlight the importance of direct examiner engagement in this art unit, where the 43.9 percent allowance rate presents a significant hurdle.
| App # | Title | Status | Assignee |
|---|---|---|---|
| 18579135 | METHODS FOR HAIR GROWTH | Final Rejection | THE REGENTS OF THE UNIVERSITY OF MICHIGAN |
| 16975043 | PARENTERAL FORMULATION MATERIALS AND METHODS FOR 40-O-CYCLIC HYDROCARBON ESTERS AND RELATED STRUCTURES | Non-Final OA | Biotronik AG |
| 18396175 | MATERNAL VITAMIN B2 ADMINISTRATION FOR THE PREVENTION OF INCREASED ADIPOSITY, OVERWEIGHT OR OBESITY IN THE OFFSPRING | Final Rejection | SOCIÉTÉ DES PRODUITS NESTLÉ S.A. |
| 17044684 | DIETARY BUTYRATE | Final Rejection | SOCIETE DES PRODUITS NESTLE S.A. |
| 18045793 | Polytherapy Modulating Cathelicidin Gene Expression Modulation for The Treatment of Alzheimer's Disease and Other Conditions | Non-Final OA | The Board of Trustees of the Leland Stanford Junior University |
| 17425894 | MITOCHONDRIA-TARGETED ISOKETAL/ISOLEVUGLANDIN SCAVENGERS | Final Rejection | Vanderbilt University |
| 18261590 | POWDEROUS COMPOSITION(II) | Final Rejection | DSM IP ASSETS B.V. |
| 18684645 | HETEROCYCLIC COMPOUNDS AS SEROTONIN (5-HT) 5-HT2A AND 5-HT2C RECEPTOR POSITIVE ALLOSTERIC MODULATORS | Final Rejection | The Board of Regents of The University of Texas System |
| 17956249 | DISULFIRAM AND OTHER REDOX-RELATED COMPOSITIONS FOR BRAIN TUMORS | Final Rejection | Texas Tech University System |
IP Author analyzes examiner patterns and generates tailored response strategies with the highest chance of allowance.
Build Your Strategy43.9% of resolved applications examined by Ibrahim D Bori were allowed (615 resolved cases), compared with 60.6% across Art Unit 1622 over the last five years.
This examiner's interview lift is +39.0 percentage points: the difference in allowance rate between resolved applications that had an examiner interview and those that did not.
Applications allowed by Ibrahim D Bori took 1,258 days on average from filing to allowance.
Ibrahim D Bori examines applications in Art Unit 1622 in Tech Center 1600 (Biotechnology & Pharmaceuticals).
